Salinomycin News and Research

RSS

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021

Scientists identify nine potential new COVID-19 treatments

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

2 Apr 2021

Study identifies a host of agents with anti-SARS-CoV-2 potential

A team of researchers at the Genomics Research Center, Academia Sinica, in Taiwan, evaluated the efficacy of 2,855 agents against SARS-CoV-2.

22 Jan 2021

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

FDA approved drugs active against COVID-19

With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.

23 Jun 2020

Antibiotic X-206 effective against SARS-CoV-2 in vitro

The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.

16 Jun 2020

Combination of nelfinar and amodiaquine shows promise for treating COVID-19

Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.

15 Jun 2020

Lund researchers develop fluorescent variant of a molecule that inhibits cancer stem cells

A team of researchers at Lund University in Sweden has developed a fluorescent variant of a molecule that inhibits cancer stem cells.

25 Jun 2018

Eisai, Verastem partner for next-generation of small molecule Wnt inhibitors

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced a research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors.

12 Jul 2012

Discovery of compounds that selectively kills cancer stem cells

The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.

13 Aug 2009

Researchers tackle aggressive cancer cells head on

A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.

13 Aug 2009